MeiraGTx price target lowered to $22 from $27 at RBC Capital

RBC Capital analyst Luca Issi lowered the firm’s price target on MeiraGTx to $22 from $27 but keeps an Outperform rating on the shares. The analyst cites the company’s Q4 earnings miss and higher operating expenditure, though the firm remains positive on the stock’s "undemanding valuation" and clinical proof of concept across eye, salivary glands, and CNS. RBC Capital further notes that MeiraGTx’s phase I dosing for Parkinson’s is underway, with enrollment completion anticipated by Q3.